Navigation Links
AcelRx Pharmaceuticals Receives First U.S. Patent for Small-Volume Oral Transmucosal Dosage Forms
Date:6/20/2012

-looking statements, including, but not limited to, statements related to AcelRx Pharmaceuticals' patent portfolio, including the useful life of the U.S. patent for a method of treating pain by administering a small-volume solid tablet containing sufentanil by adhering to the oral mucosa, the continued expansion of its patent protection, market exclusivity, its ability to protect its proprietary technology, the scope of patent protection, and issued and planned or anticipated future clinical development of AcelRx Pharmaceuticals' product candidates, including the initiation of the third Phase 3 clinical studies for ARX-01, the timing of the top-line data from all three clinical trials, the timing of submission of an NDA with the FDA, and the therapeutic potential of AcelRx Pharmaceuticals' product candidates.  These forward-looking statements are based on AcelRx Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties.    AcelRx Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of AcelRx Pharmaceuticals' product development activities and clinical trials; the success of its patent prosecution strategy; its ability to protect its proprietary technology, including the risks that pending patent applications may not result in issued patents; its ability to obtain sufficient financing to complete development and registration of its product candidates in the United States and Europe; its ability to obtain and maintain regulatory approvals of its product candidates; the market potential for its product candidates; and other risks detailed in the "Risk Factors" and elsewhere in AcelRx Pharmaceuticals' U.S. Securities and Exchange Commission filings, including its Annual Report on Form 10-K for the Year
'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology news :

1. Fish show autism-like gene expression in water with psychoactive pharmaceuticals
2. Tokai Pharmaceuticals galeterone well-tolerated in patients with advanced prostate cancer
3. From scourge to saint: E. coli bacteria becomes a factory - to make cheaper, faster pharmaceuticals
4. UCLAs Yi Tang receives Presidential Green Chemistry Challenge Award from EPA
5. Leading statistician receives national citation award
6. Dr. Karen Lloyd receives WHOIs Holger W. Jannasch Visiting Scholar Award
7. SF State biology department receives $1.5 million to support science teaching
8. SRI Sarnoffs Iris on the Move® N-Glance™ Identification System Receives Lenel Factory Certification
9. Washington University receives $8 million to lead international childhood malnutrition effort
10. UC Riverside receives grant for global health and development research
11. UC Riverside plant cell biologist receives top scientific honor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... June 27, 2014  Pomerantz LLP has filed ... ("Provectus" or the "Company")(NYSE-MKT: PVCT) and certain of ... States District Court, Middle District of ... of a class consisting of all persons or ... between December 17, 2013 and May 22, 2014, ...
(Date:7/10/2014)... July 2, 2014 It is a great ... the appointment of the world-renowned Thoracic and Cardiovascular surgeon, ... Dr. Ginsburg, with over 34 years of ... Hospital and Good Samaritan Regional Medical Center. Dr. Ginsburg ... late 1980,s and is considered an expert in the ...
(Date:7/10/2014)... , July 7, 2014 Fingerprint Cards, ... major design win (DW). A Chinese Top 5 smartphone OEM ... start of mass production in October 2014.   ... Top 5 smartphone OEM, which has a planned date for ... target sales volume for this phone of 3 million units. ...
Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2
... (October 5, 2010) -- Protein molecules inside cells ... forces exerted by all the other molecules in ... models are necessarily built around much greater driving ... Journal of Chemical Physics investigates the ...
... State University researchers have discovered a rare oasis of life ... bottom of Yellowstone Lake. A colony of moss, worms ... the water is inky black, about 90 degrees Fahrenheit, and ... in the September issue of Geobiology. The vent is ...
... Oct. 4, 2010 -- Supercomputer simulations at the Department of ... nucleic acids could have contributed to the origins of life. ... who directs ORNL,s Center for Molecular Biophysics and holds a ... to probe an organic chemical reaction that may have been ...
Cached Biology News:Montana State team finds rare oasis of life on floor of Yellowstone Lake 2Montana State team finds rare oasis of life on floor of Yellowstone Lake 3Montana State team finds rare oasis of life on floor of Yellowstone Lake 4Powerful supercomputer peers into the origin of life 2
(Date:7/10/2014)... 2014 Robert Harman, DVM, Founder and CEO ... proud to announce the relaunch of his highly informative blog, ... series called “ What are Stem Cells ?” Dr. ... straightforward foundation in the basics of stem cell therapy so ... right type of treatment when considering regenerative medicine. , A ...
(Date:7/10/2014)... July 10, 2014 Senior supply chain ... professional associations, addressed the challenges of “Reducing Cost, Lead ... Industries” through strategic sourcing. Describing the partnership of the ... Supply Chain Management Institute ( SCMI) of the ... June 24 at the Kroc Institute of Peace and ...
(Date:7/10/2014)... July 10, 2014  Kainos Capital, a firm specializing ... announced that it has acquired the Slim-Fast brand from ... business. Terms of the transaction were not disclosed. ... replacement business that markets ready-to-drink shakes, powders, bars and ... and in the United Kingdom ...
(Date:7/10/2014)... July 10, 2014   Ceres, Inc . (Nasdaq: ... company, announced today financial results for the three months ... its business. Ceres reported that the company ... performance this growing season in Brazil, which concluded in ... company,s sorghum evaluation areas for part of the growing ...
Breaking Biology Technology:Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Kainos Capital Acquires Slim-Fast From Unilever 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... students for work in ... medical manufacturing, COLUMBUS, Ohio, ... other consumer products are being leveraged by,Ohio,s growing bioscience industry to ... of skilled labor to sustain,the unprecedented growth of the bioscience industry, ...
... 30 Vanda Pharmaceuticals,Inc. (Nasdaq: VNDA ), ... of clinical-stage product candidates for central,nervous system disorders, ... quarter ended September 30, 2008., Vanda reported ... of 2008 of $3.8 million, compared to $5.5 ...
... DIEGO, Oct. 30 Prometheus Laboratories Inc., ... the U.S.,Patent and Trademark Office (USPTO) has ... PROMETHEUS(R) Thiopurine Metabolites, a,diagnostic test that enables ... reach and maintain desired therapeutic levels. The ...
Cached Biology Technology:Rapidly Expanding Ohio Bioscience Industry Drives New Workforce Training Program 2Rapidly Expanding Ohio Bioscience Industry Drives New Workforce Training Program 3Vanda Pharmaceuticals Reports Third Quarter 2008 Results 2Vanda Pharmaceuticals Reports Third Quarter 2008 Results 3Vanda Pharmaceuticals Reports Third Quarter 2008 Results 4Vanda Pharmaceuticals Reports Third Quarter 2008 Results 5Vanda Pharmaceuticals Reports Third Quarter 2008 Results 6Vanda Pharmaceuticals Reports Third Quarter 2008 Results 7Vanda Pharmaceuticals Reports Third Quarter 2008 Results 8Vanda Pharmaceuticals Reports Third Quarter 2008 Results 9Vanda Pharmaceuticals Reports Third Quarter 2008 Results 10Prometheus Strengthens Intellectual Property Portfolio with Newly Issued Patents for Thiopurine Metabolite Testing 2
Collected from 8-12 week old New Zealand or Californian rabbits. Aseptically collected and processed to minimize hemolytic activity. Pricing: $60/unit for 1 - 10 units...
Donor Goat Serum...
GeneRacer is an advanced RACE (rapid amplification of cDNA ends) technique that improves the efficiency of amplifying full-length 5' and 3' cDNA ends. With the GeneRacer Kit you can:...
One-step, microplate or cuvet, colorimetric, linear detection range 0.7 mg/dL to 35 mg/dL. Procedure: 5 min....
Biology Products: